Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × talazoparib × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 22 Genitourinary 11 Gynecologic 8 Tumor-Agnostic 7 Other hematologic neoplasm 6 Thoracic 4 Gastrointestinal 4 Sarcoma 2 Other solid neoplasm 2 CNS 2 Plasma cell 1 NET 1 Myeloid 1 Lymphoid 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 30 Everolimus 17 Magnetic Resonance Spectroscopy 13 gallium Ga 68 dotatate 10 Temozolomide 10 Capecitabine 10 Nivolumab 9 lanreotide 8 177Lu-octreotide, DOTA(0)-Tyr(3)- 8 cabozantinib 7 Positron Emission Tomography Computed Tomography 7 Somatostatin 6 Octreotide 6 Ga(III)-DOTATOC 6 90Y-octreotide, DOTA-Tyr(3)- 6 3-Iodobenzylguanidine 6 pembrolizumab 5 Lutetium-177 5 Fluorodeoxyglucose F18 5 Carboplatin 5 telotristat ethyl 4 pasireotide 4 avelumab 4 Ipilimumab 4 Bevacizumab 4 Al18F-NOTA-octreotide 4 surufatinib 3 lenvatinib 3 fluorodopa F 18 3 copper dotatate CU-64 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05053854 2025-02-20

PARLuNET

Peter MacCallum Cancer Centre, Australia

Phase 1 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡